Brokers Set Expectations for HeartSciences Q4 Earnings

HeartSciences Inc. (NASDAQ:HSCS) – Research analysts at Maxim Group issued their Q4 2026 earnings estimates for shares of HeartSciences in a research note issued to investors on Wednesday, July 1st. Maxim Group analyst A. Klee expects that the company will earn ($0.78) per share for the quarter. The consensus estimate for HeartSciences’ current full-year earnings is ($3.28) per share. Maxim Group also issued estimates for HeartSciences’ Q1 2027 earnings at ($0.81) EPS, Q2 2027 earnings at ($0.73) EPS, Q3 2027 earnings at ($0.74) EPS, Q4 2027 earnings at ($0.67) EPS, FY2027 earnings at ($2.93) EPS, Q1 2028 earnings at ($0.72) EPS, Q2 2028 earnings at ($0.67) EPS, Q3 2028 earnings at ($0.51) EPS, Q4 2028 earnings at ($0.35) EPS and FY2028 earnings at ($2.21) EPS.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HeartSciences in a report on Wednesday, June 24th. Ascendiant Capital Markets lowered their price target on HeartSciences from $9.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, March 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $8.00.

HeartSciences Trading Down 5.1%

Shares of HeartSciences stock opened at $2.79 on Friday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.04 and a current ratio of 1.19. The company has a market capitalization of $8.87 million, a P/E ratio of -0.56 and a beta of 1.78. HeartSciences has a 1 year low of $1.63 and a 1 year high of $6.47. The company’s fifty day moving average is $2.05 and its two-hundred day moving average is $2.50.

Hedge Funds Weigh In On HeartSciences

An institutional investor recently raised its position in HeartSciences stock. Geode Capital Management LLC raised its position in HeartSciences Inc. (NASDAQ:HSCS) by 110.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 26,928 shares of the company’s stock after acquiring an additional 14,150 shares during the period. Geode Capital Management LLC owned approximately 0.85% of HeartSciences worth $83,000 at the end of the most recent reporting period. Institutional investors own 17.24% of the company’s stock.

Key Headlines Impacting HeartSciences

Here are the key news stories impacting HeartSciences this week:

• Neutral Sentiment: Maxim Group initiated or updated earnings forecasts for HeartSciences, projecting losses of $0.78 per share in Q4 2026, $0.81 in Q1 2027, $0.73 in Q2 2027, $0.74 in Q3 2027, and $0.67 in Q4 2027, followed by FY2027 losses of $2.93 per share. HeartSciences stock page
• Neutral Sentiment: The firm also forecast narrower losses in FY2028, estimating $2.21 per share, with quarterly losses of $0.72 in Q1 2028, $0.67 in Q2 2028, $0.51 in Q3 2028, and $0.35 in Q4 2028, suggesting improving profitability expectations over time. HeartSciences stock page
• Neutral Sentiment: Because these estimates are still negative but trending less so, the reports may support a modestly constructive view on the stock, though the updates do not by themselves signal a major catalyst. HeartSciences stock page

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.